尽管达到狼疮低疾病活动状态或缓解定义,系统性红斑狼疮患者健康相关生活质量仍较差:临床试验结果
该研究分析四项贝利尤单抗III期试验(n=2406)数据,评估SLE患者52周治疗后达到LLDAS或DORIS缓解及持续缓解时健康相关生活质量(HRQoL)不良的患病率。结果显示,达到LLDAS、缓解、持续LLDAS和持续缓解的患者中,SF-36 PCS不良比例分别为15.7%、13.6%、14.3%和9.0%,MCS不良比例分别为12.5%、11.4%、12.9%和14.0%,提示当前治疗目标定义未完全涵盖患者健康感受。
要点
- 达到LLDAS或DORIS缓解的SLE患者中仍有相当比例报告HRQoL不良。
- SF-36生理功能域不良频率最高(24.0%-26.3%),EQ-5D疼痛/不适维度不良频率最高(27.9%-28.7%)。
- 52周内达到治疗目标者所有HRQoL结局显著改善,但PCS评分仍低于人群常模。
核心结论
- 尽管达到LLDAS或DORIS缓解,相当比例SLE患者报告HRQoL不良,提示当前治疗目标定义未完全捕捉患者健康视角。
研究设计与样本
- 分析四项贝利尤单抗治疗SLE的III期试验(BLISS-52、BLISS-76、BLISS-SC、EMBRACE;n=2406)数据,评估52周治疗干预后HRQoL。
主要发现
- 第52周时,LLDAS、缓解、持续LLDAS和持续缓解患者中,SF-36 PCS不良比例分别为15.7%、13.6%、14.3%和9.0%。
- 第52周时,LLDAS、缓解、持续LLDAS和持续缓解患者中,SF-36 MCS不良比例分别为12.5%、11.4%、12.9%和14.0%。
- 生理功能域不良频率最高(24.0%-26.3%),18.5%-26.2%患者FACIT-F评分<30。
- EQ-5D维度中疼痛/不适不良体验频率最高(27.9%-28.7%)。
- 52周研究期间达到治疗目标者所有HRQoL结局显著改善,但PCS评分仍低于人群常模。
关键数值与推荐
- 持续LLDAS/缓解定义为至少两次访视持续LLDAS/缓解并维持至第52周。
- HRQoL不良定义为SF-36 PCS/MCS及域评分≤常模第五百分位、FACIT-F评分<30、EQ-5D五维度中任一项回答「一些/中度问题」或「极度/重大问题」。
临床怎么用
- 在临床实践中,即使SLE患者达到LLDAS或DORIS缓解,仍需关注其HRQoL,因当前治疗目标定义未完全反映患者健康感受。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prevalence of poor health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) in Lupus Low Disease Activity State (LLDAS) or Definitions of Remission in SLE (DORIS) remission and sustained LLDAS or sustained DORIS remission, after a 52-week therapeutic intervention. METHODS: We analysed data from four phase III trials of belimumab in SLE (BLISS-52, BLISS-76, BLISS-SC, EMBRACE; n=2406). Sustained LLDAS/remission was defined as persistent LLDAS/remission for at least two visits, maintained through week 52. Poor HRQoL was defined as Short Form-36 (SF-36) physical/mental component summary (PCS/MCS) and domain scores ≤the normative fifth percentile, Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scores <30 and responses of 'some/moderate problems' or 'extreme/major problems' in any of the five dimensions of the three-level version of EuroQol 5-Dimension (EQ-5D) health questionnaire. RESULTS: At week 52, among patients in LLDAS, remission, sustained LLDAS and sustained remission, 15.7%, 13.6%, 14.3% and 9.0% reported poor SF-36 PCS, and 12.5%, 11.4%, 12.9% and 14.0% reported poor SF-36 MCS scores, respectively. The highest frequencies were reported in the physical functioning domain (24.0%-26.3%), while 18.5%-26.2% reported FACIT-F scores 30. Among EQ-5D dimensions, pain/discomfort yielded the greatest frequencies of poor HRQoL experience (27.9%-28.7%). While significant improvements were observed among patients achieving the treatment goals in all HRQoL outcomes over the 52-week study period, PCS scores remained below population norms. CONCLUSIONS: Despite LLDAS or DORIS remission, notable proportions of SLE patients report poor HRQoL, indicating that current therapeutic goal definitions do not fully capture patients' perspectives of health.
引用
- Parodis I, Lindblom J, Palazzo L, et al. Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting. RMD Open. 2025. PMID: 41173511. doi:10.1136/rmdopen-2025-006061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。